Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic ...
CHICAGO, March 17, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...
Gvoke VialDx will be available as a 1-count or 10-count package of 1 mg per 0.2 mL single-dose vials. Indications and Important Safety Information Gvoke is an antihypoglycemic agent indicated for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback